Get started

PHARMA

IOLCP SHORT TERM ANALYSISGuys entry possible but high risky. no entry @cmp no entry @cmp no entry @cmp enter only if u get clear reversal. other wise can see a good fall in the stock. like i said it's just a beginning of something..maybe a good fall..or a sharp recovery short term enter if possible @ 580-550 range strict sl 500 trgt 800-900-1000-1200 ++ once again guys strick sl @500 if the stock reject from current level or betweeen 580-90 range it will hit 800++ sooon
NSE:IOLCPLong
by ANKITHSHAJU
3
LAURUS LAB || CHANNEL STUCK (15Min) || BUY ZONE1. We started with the Daily chart and saw stock to be near the upper resistance levels. Overall trend being positive ! 2. We came down to 4H and 1H chart to mark all the important key levels and support zones. 3. We came down to 30Min and 15Min to find the channel pattern. 4. On a 5 min chart the price has already retested it's key support level and is good for a buy trade. ---------- Hi! One should always trade what they see and not what they feel. I might be wrong or right but what matters the most is how much you are willing to loose... Happy investing ! Don't forget to hit like and comment your doubts.
NSE:LAURUSLABSLong
by Abhishek_TradersSin
2
NURECA | IPO Details ....Started @ 15 / FEB /2021 ( Today) 🎯NURECA IPO REVIEW- Introduction to NURECA- -Incorporated on 2nd November 2016 @Delhi. -B2C Home healthcare and wellness product company. -95% Revenue online. -1 manufacturing unit-@Chandigarh. -3 Brands. What does the company do- -company enables people with tools to effectively monitor chronic illness and upgrade their lifestyles. -company engaged in the business of home healthcare and wellness products, which offers quality, durability, functionality, usability, and innovative designs. -company tries to provides the home health care sector with innovation. -Nureca company is the first digital company wherein they sell the products through online channel partners such as e-commerce players, distributors, and retailers. The following brands are currently used by the Company- -Dr. Trust: they provide the users to effectively monitor chronic illness and try to upgrade their lifestyle. -Dr. Physio: This brand provides electric massagers, wheelchairs, and walkers. -Trump: This brand provides the Mother and Child Care category. NURECA PRODUCTS- -Chronic Device Products- products such as blood pressure monitors, pulse oximeters, thermometers, nebulizers, self-monitoring glucose devices, humidifier ands teamers. -Orthopedic Products-such as wheelchairs, walkers and physiotherapy electric massagers. -Mother and Child Products- such as breast pumps, bottle sterilizers, bottle warmers, car seats and baby carrycots. -Nutrition Supplements- such as fish oil, multivitamins, probiotics, biotin, apple cider and vinegar. -Lifestyle Products- such as smart scales, aroma diffusers and fitness trackers. NURECA'S Strength- -Most of the products of NURECA is outsourced. -Due to this their cost of production is low comparatively. -Asset light model. -It increased the production capacity. -Bring product on semi-knocked down condition. -V-shaped recovery. -Nureca has a strong portfolio of products and a consistent focus on quality and innovation. Financial Analysis- -It has grown at a CAGR of 122.49%. As for the total assets, that has grown at a CAGR of 117.12%. -The profits after tax, the growth rate is more moderate. -Over the past three years, the net income has grown at a CAGR of 41.42%. -The negative net cash flow from operating activities has grown at a CAGR of above 780%. -the increasing burden of long-term debt. From Rs. 43 lakhs in 2019 to Rs. 9.77 crores in 2020 is an increase of over 2000%. -If this debt burden continues to increase at this rate, it will create pressure on Nureca’s balance sheet. -It was valued at Rs. 20,757 crores in 2019. By 2025, this market is expected to grow to Rs. 38,920.70 crores. -It has grown from $24 billion in 2017 to $84 billion in 2021. -In India especially, at least 33% of the population resorts to online shopping as opposed to conventional shopping outlets. -Nutritional products, Rs. 17,840 crores in 2019 and it is expected to grow to Rs. 33,368 crores in 2025. -Coming to the market for orthopedic products, in 2019, it was sized at Rs. 682.80 crores. This is expected to grow to Rs. 1,162.90 crores by 2025. The predicted CAGR, in this case, is 9.2%. The graph below shows the growing market size over the years. -The demand for chronic disease products is, of course, fairly inelastic in nature. -Owing to the steadily increasing wave of chronic diseases, this demand is expected to rise in the future. -By 2026, 12.5% of the population is expected to be geriatric in nature i.e. they will be above the age of 60. This means the demand for health-care products will only increase. Business model- -Nureca is a B2C company engaged in the business of home healthcare and wellness products, -it offers quality, durability, functionality, usability and innovative designs. -Voltas enables their customers with tools to help them monitor chronic illness and other diseases, to upgrade their lifestyle. Risk- -it faces stiff competition from organized and unorganized players, which leads to pricing pressure. -it reduced margins and lower profitability. -Home-health products are considered consumer-grade, due to concerns regarding the accuracy measures of products. -The company does not enter into long-term contracts for the manufacturing of its products and any manufacturing-related disruption could seriously impact its business -The company also depends heavily on its channel partners such as third-party e-commerce players, distributors, and retailers. Any failure to manage the distribution network efficiently will adversely affect its performance. IPO details- IPO Date February 15, 2021 to February 17, 2021 Issue Type Book Built Issue IPO Issue Size Rs.100 Crore Fresh Issue Rs.100 Crore Face Value Rs.10 per equity share IPO Price Rs.396 to Rs.400 per equity share Market Lot 35 shares MinOQ 35 shares Listing At BSE, NSE Promoter's holding- -Saurabh Goyal 46.67% -Payal Goyal 46.67% Object of the issue- -To meet the working capital requirements of the business. -To meet the general corporate purpose. 🙏FOLLOW for more ! 👍LIKE if think is useful ! ✍COMMENT Below your view !
NSE:RELIANCEEducation
by ReviveTraders
11